Physician profile
Jon P Burdzy
NPI 1205854510
$3,122.80
in general payments reported to CMS, 2019-2025
29 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $200 · 2021: $220 · 2022: $105 · 2023: $631 · 2024: $726 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,798 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,797.71 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $442.96 | 2019-2025 | Evenity, Prolia, Repatha |
| Boston Scientific Corporation | $305.90 | 2023-2025 | Intracept, Watchman Flx |
| Novo Nordisk INC | $298.80 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Lilly USA, LLC | $209.26 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $197.29 | 2021-2025 | Synthroid, Ubrelvy |
| Pfizer INC. | $192.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $170.35 | 2019-2023 | Farxiga |
| Astellas Pharma US INC | $141.43 | 2021-2025 | Veozah |
| Merck Sharp & Dohme LLC | $129.79 | 2020-2024 | Gardasil 9, Gardasil |
| Gilead Sciences, INC. | $125.35 | 2019 | |
| Dexcom, INC. | $118.10 | 2024 | Dexcom G7 Gss (161) |
| Abbott Laboratories | $114.37 | 2020-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Amarin Pharma, INC. | $111.70 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.44 | 2020-2024 | Jardiance |
| Exact Sciences Corporation | $72.17 | 2024-2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $70.98 | 2019 | |
| Teleflex LLC | $63.17 | 2023 | Urolift |
| Novartis Pharmaceuticals Corporation | $36.07 | 2019-2024 | |
| Glaxosmithkline, LLC. | $30.37 | 2024-2025 | Shingrix, Arexvy |
| Currax Pharmaceuticals LLC | $28.63 | 2021 | |
| Nevro Corp. | $24.87 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.47 | 2023 | Rexulti, Abilify Asimtufii |
| Sumitomo Pharma America, INC. | $22.34 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $17.49 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.20 | 2019 | |
| Shield Therapeutics INC | $16.34 | 2024 | |
| Optinose US, INC. | $15.69 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.69 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Burdzy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.